COMMUNIQUÉS West-GlobeNewswire

Panbela Provides Business Update and Reports Q2 2024 Financial Results

13/08/2024 - 22:10

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

13/08/2024 - 22:10

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 [...]

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

13/08/2024 - 22:08

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 – – Solid plans [...]

UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq

13/08/2024 - 22:06

AI Technology to Assist Clinicians to Drive Better Outcomes in Brain Health TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial [...]

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13/08/2024 - 22:05

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or [...]

Glass House Brands Reports Record Setting Second Quarter 2024 Financial Results

13/08/2024 - 22:05

- Greenhouse 5 completed its first full quarter of production and sales in Q2, outperforming expectations - Record quarterly highs included consolidated revenue and gross profit, wholesale biomass revenue and gross [...]

ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes

13/08/2024 - 22:05

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% [...]

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

13/08/2024 - 22:05

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement [...]

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

13/08/2024 - 22:05

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical [...]

Psychemedics Corporation Reports Second Quarter 2024 Financial Results

13/08/2024 - 22:05

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30 [...]

Trinity Biotech to Announce Q2 2024 Financial Results

13/08/2024 - 22:05

Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on [...]

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

13/08/2024 - 22:05

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Abstract accepted for BDC-4182, a claudin 18.2-targeting Boltbody TM ISAC at the Society for Immunotherapy [...]

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

13/08/2024 - 22:05

PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

13/08/2024 - 22:05

Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen First Patient Treated with FT522 CAR NK Cell [...]

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13/08/2024 - 22:05

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature [...]

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

13/08/2024 - 22:05

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals Entered into a joint development agreement [...]

Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024

13/08/2024 - 22:05

RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and [...]

NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

13/08/2024 - 22:05

-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 -- -- Increased full-year 2024 revenue guidance to $76 million to $78 million -- -- Demonstrated continued operating discipline as evidenced by [...]

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

13/08/2024 - 22:05

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In [...]